NKGEN Biotech

NKGEN Biotech

  • Founded: 2017
  • Location: Santa Ana, CA
  • Employee range: 50 - 200
  • Clinical stage: Clin1
  • Therapy area: Neurodegenerative Disease
  • Drug types: ONC, NEU
  • Lead product: SNK01
  • Product link: https://nkgenbiotech.com/pipeline/
  • Funding: 10-100M
  • Investors: SPAC planned Apr 2023



job board

Short description:

Autologous and allogenic Natural Killer cell therapy

Drug notes:

Also Clin1 solid tumors; SNK02 Clin0 undisclosed oncology targets; CAR-SNK02 RD/Clin0 HER2+ solid tumors

Long description:

NKGen Biotech is harnessing the power of the immune system to fight diseases. Their treatments target natural killer (NK) cells in order to enhance the patient’s immune system for effective targeting and elimination of abnormal cells. NK cells release toxic substances such as perforin or granzymes to cause death of abnormal cells. Decreased activity in NK cells occurs with aging and can contribute to both neurodegenerative and oncological conditions. NKGen is developing and commercializing innovative NK cell therapies, using autologous, allogeneic, and CAR-NK approaches. Their goals are to improve patient lives through safe and natural cell therapy treatments and become a global leader in immune cell therapeutics. Their US headquarters is a state-of-the-art cGMP manufacturing facility.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com